HomeAI · summaries
Storia in 3 fonti
'Going for our own moonshot': Parabilis CEO on biotech's record IPO
Parabilis Medicines CEO Mathai Mammen speaks about the biotech's record $670M IPO, its desmoid tumor pipeline and plans beyond oncology.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Parabilis sets a record with a $670M biotech IPO
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion…
- ·
endpoints.news
Parabilis' $670M IPO sets new biotech record, will fund cancer drug
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide.
